Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CARGO Therapeutics, Inc. - Common Stock (NQ:CRGX)

4.150 -0.040 (-0.95%)
Streaming Delayed Price Updated: 12:56 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CARGO Therapeutics, Inc. - Common Stock

CARGO Therapeutics Provides Corporate Update
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX
From DJS Law Group
Via Business Wire
CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics to Participate in Upcoming Investor Conferences
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics to Participate in Upcoming Investor Conferences
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – 
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
From Cargo Therapeutics, Inc.
Via GlobeNewswire
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Cargo Therapeutics, Inc.
Via GlobeNewswire
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
From Cargo Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.